PreMarketData.com BioElectronics Corp. (Pink Sheets: BIEL) News Alert
Study tests the effectiveness of ActiPatch Therapy versus acetaminophen (Extra Strength Tylenol(R))
(EMAILWIRE.COM, November 17, 2009 ) Las Vegas NV - BioElectronics Corp. (Pink Sheets: BIEL). Monday’s Headline: BioElectronics Technology More Effective Than Extra Strength Tylenol(R) in Reducing Muscle Soreness in Clinical Study
BioElectronics Corp. (Pink Sheets: BIEL) on Monday after the closing bell announced that its disposable drug-free anti-inflammatory devices proved to be significantly more effective than acetaminophen in a clinical study of Delayed Onset Muscle Soreness (DOMS). According to the company’s press release the study included more than 100 healthy male and female college athletes and trainers which were given a vigorous resistance exercise regimen to induce DOMS.
The study tested the effectiveness of ActiPatch Therapy versus acetaminophen in reducing the pain of Delayed Onset Muscle Soreness, a condition associated with increased physical exertion. Participants were divided randomly into three groups; a group that used ActiPatch for two days, a control group that received no treatment, and a third group that was to be treated with acetaminophen.
Sheena Kong, M.D. the principal investigator commented, "The study was conclusive showing that the ActiPatch treated volunteers had significantly less pain than those in either the acetaminophen or control groups. Also of note was the fact that some of the participants assigned to the acetaminophen group were eliminated from the results because they expressed reservations about consuming the drug." For more information CONTACT: Media/IR Joe Noel (925) 922-2560
Sector: Biomedical
Industry: Biotechnology
Get ahead of the market with www.PreMarketData.com ALERTS for FREE!
Sign up for our FREE newsletter at www.premarketdata.com
Join us on twitter at www.twitter.com/premarketdata
If it’s stock market news, GET it at www.PreMarketData.com
Get valuable exposure for your company through www.PreMarketData.com by contacting us at:
Contact: info@PreMarketData.com
Join PreMarketData.com’s large community of Wall St. professionals to receive news, views and alerts. It’s always free to our subscribers at www.PreMarketData.com
About - PreMarketData.com is a premier information destination for breaking News, Profiles, and Alerts on Micro, Small, Mid, and Large Cap Stocks. PreMarketData.com publishes pre-market, early and mid-session reports including Op-Ed and informational pieces globally and on its web site. Join other Wall Street professionals and subscribe to our FREE newsletter giving you a head start on what's hot in the market.
Disclaimer
PreMarketData.com is a wholly owned subsidiary of Investors Direct Inc. The material contained in this is release is intended to be strictly informational. This article may contain forward looking statements. The accuracy and completeness of the information supplied is not warranted and is derived from a variety of sources and third parties which may or may not be reliable. Investors Direct Inc. and PreMarketData.com disclaim any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may also contain technical inaccuracies or typographical errors. This material is being provided for informational purposes only. PreMarketData.com is NOT a registered investment advisor or a broker dealer. This information neither is, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by Investors Direct Inc., or PreMarketData.com. PreMarketData.com does not offer or provide any investment advice or opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make. Such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.
PreMarketData.com or its officers and directors may hold positions in the companies mentioned in this report. PreMarketData.com may also receive compensation from companies mentioned in this report so please read our compensation disclosure which can be found at www.PreMarketData.com. At this time PreMarketData.com has not been compensated by any of the companies mentioned in this report.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and PreMarketData.com undertakes no obligation to update such statements.
At the time of this report PreMarketData.com holds no position in BIEL.
Always do your own due diligence.
Visit our web site, www.PreMarketData.com for further risks and disclosures.
BioElectronics Corp. (Pink Sheets: BIEL) on Monday after the closing bell announced that its disposable drug-free anti-inflammatory devices proved to be significantly more effective than acetaminophen in a clinical study of Delayed Onset Muscle Soreness (DOMS). According to the company’s press release the study included more than 100 healthy male and female college athletes and trainers which were given a vigorous resistance exercise regimen to induce DOMS.
The study tested the effectiveness of ActiPatch Therapy versus acetaminophen in reducing the pain of Delayed Onset Muscle Soreness, a condition associated with increased physical exertion. Participants were divided randomly into three groups; a group that used ActiPatch for two days, a control group that received no treatment, and a third group that was to be treated with acetaminophen.
Sheena Kong, M.D. the principal investigator commented, "The study was conclusive showing that the ActiPatch treated volunteers had significantly less pain than those in either the acetaminophen or control groups. Also of note was the fact that some of the participants assigned to the acetaminophen group were eliminated from the results because they expressed reservations about consuming the drug." For more information CONTACT: Media/IR Joe Noel (925) 922-2560
Sector: Biomedical
Industry: Biotechnology
Get ahead of the market with www.PreMarketData.com ALERTS for FREE!
Sign up for our FREE newsletter at www.premarketdata.com
Join us on twitter at www.twitter.com/premarketdata
If it’s stock market news, GET it at www.PreMarketData.com
Get valuable exposure for your company through www.PreMarketData.com by contacting us at:
Contact: info@PreMarketData.com
Join PreMarketData.com’s large community of Wall St. professionals to receive news, views and alerts. It’s always free to our subscribers at www.PreMarketData.com
About - PreMarketData.com is a premier information destination for breaking News, Profiles, and Alerts on Micro, Small, Mid, and Large Cap Stocks. PreMarketData.com publishes pre-market, early and mid-session reports including Op-Ed and informational pieces globally and on its web site. Join other Wall Street professionals and subscribe to our FREE newsletter giving you a head start on what's hot in the market.
Disclaimer
PreMarketData.com is a wholly owned subsidiary of Investors Direct Inc. The material contained in this is release is intended to be strictly informational. This article may contain forward looking statements. The accuracy and completeness of the information supplied is not warranted and is derived from a variety of sources and third parties which may or may not be reliable. Investors Direct Inc. and PreMarketData.com disclaim any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may also contain technical inaccuracies or typographical errors. This material is being provided for informational purposes only. PreMarketData.com is NOT a registered investment advisor or a broker dealer. This information neither is, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by Investors Direct Inc., or PreMarketData.com. PreMarketData.com does not offer or provide any investment advice or opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make. Such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.
PreMarketData.com or its officers and directors may hold positions in the companies mentioned in this report. PreMarketData.com may also receive compensation from companies mentioned in this report so please read our compensation disclosure which can be found at www.PreMarketData.com. At this time PreMarketData.com has not been compensated by any of the companies mentioned in this report.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and PreMarketData.com undertakes no obligation to update such statements.
At the time of this report PreMarketData.com holds no position in BIEL.
Always do your own due diligence.
Visit our web site, www.PreMarketData.com for further risks and disclosures.
Contact Information:
Premarketdata.com
editor@premarketdata.com
Tel: 702 544 2396
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Premarketdata.com
editor@premarketdata.com
Tel: 702 544 2396
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |